Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal Cancer (HERACLES)

October 29, 2018 updated by: Fondazione del Piemonte per l'Oncologia

Open-Label, Phase II Study of Trastuzumab in Combination With Lapatinib (Cohort A) or Pertuzumab in Combination With Trastuzumab-emtansine (Cohort B) in Patients With HER2-positive Metastatic Colorectal Cancer: the HERACLES (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification)Trial

This is a Phase II multi-center 2-sequential cohorts trial, designed to assess the objective response rate of two anti HER2 combination in advanced disease CRC patients harbouring an amplified HER2 tumor assessed according to HERACLES Diagnostic Criteria by FISH/SISH.

Cohort A: monoclonal antibody trastuzumab, used in combination with the small molecule tyrosine kinase inhibitor lapatinib.

Cohort B, monoclonal antibody pertuzumab, used in combination with the antibody drug conjugate trastuzumab-emtansine.

Please note that cohort A accrual has been closed and endpoint already reached.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Investigators identified HER2 amplification as a potential onco-driver and marker of de novo resistance to anti-EGFR therapy in mCRC patients for which other known genetic alterations conferring resistance to anti EGFR antibodies were excluded.

Exploiting direct transfer xenografts of mCRC surgical samples in mice (xenopatients), investigators conducted a multi-arm study in HER2-amplified xenopatients showing that combinations of the dual EGFR/HER2 inhibitor lapatinib and the anti-HER2 moAb trastuzumab induced long-lasting tumor regressions, while monotherapy with lapatinib led to stabilization and monotherapy with trastuzumab was ineffective. On these findings investigators designed the HERACLES trial.

HERACLES is an open-label Phase II, 2-sequential cohorts trial, assessing the response rate (ORR) of Trastuzumab combined Lapatinib (Cohort A) or Pertuzumab combined with trastuzumab-emtansine (Cohort B), in metastatic colorectal patients harboring an amplified HER2 tumors .

HER2 positivity is centrally established by immunohistochemistry (IHC) and Silver In Situ Hybridization (SISH). To be HER2 eligible the original tumor, or the biopsied metastasis (whichever is last available), must be IHC 3+ or 2+ in more than 50% of cells, confirmed by SISH or FISH with a HER2:CEP17 ratio ≥ 2.0. For IHC a positive staining (3+) is defined as an intense membrane staining which can be circumferential, basolateral, or lateral of the tumor cells.

Study Type

Interventional

Enrollment (Anticipated)

54

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Italy
      • Bologna, Italy
        • AOU Policlinico S. Orsola Malpighi
      • Milano, Italy, 20162
        • Grande Ospedale Metropolitano Niguarda
      • Napoli, Italy
        • Seconda Universita di Napoli
      • Padova, Italy
        • Istituto Oncologico Veneto - IRCCS
      • Roma, Italy
        • Campus Biomedico
      • Torino, Italy
        • AOU Citta della Salute e della Scienza di Torino
    • Please Select
      • Candiolo, Please Select, Italy, 10060
        • Fondazione del Piemonte per l'Oncologia - IRCCS

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion criteria COHORT A

  1. Histological/confirmed adenocarcinoma of the colon or rectum with metastatic disease not amenable to salvage surgery.
  2. Pathology mandatory requirements: the original tumour specimen must be KRAS WT and SISH/FISH positive or IHC 3+ positive in more than 50% cells. Note: for immunohistochemistry a positive staining (3+) is defined as an intense membrane staining which can be circumferential, basolateral, or lateral of the tumor cells. the original paraffin block or a minimum of 15 polarized unstained slides from the original paraffin block must be made available to the Pathology Core within 15 days from registration.
  3. Age ≥18
  4. ECOG PS 0-1
  5. Measurable disease as defined by RECIST 1.1 criteria.
  6. Progression (PD) while on, or within 6 months from therapy with approved standard drugs.
  7. Unless otherwise contraindicated patients should have received and failed the following previous therapies for mCRC: fluoropyrimidines, oxaliplatin, irinotecan, cetuximab or panitumumab containing regimens. Bevacizumab is allowed
  8. Adequate haematological function as defined by: ANC > 1.5 x 109/L, platelet count >100 x 109/L, haemoglobin > 10 g/dL
  9. Adequate renal function, as defined by: creatinine < 1.5 x UNL
  10. Adequate hepatobiliary function, as defined by the following baseline liver function tests: total serum bilirubin <1.5 upper normal limit (UNL); alanine aminotransferase (ALT), aspartate aminotransferase (AST) < 2.5xUNL; alkaline phosphatase (AP) < 2.5xUNL, if total alkaline phosphatase (AP) > 2.5xUNL, alkaline phosphatase liver fraction must be < 2.5xUNL
  11. Adequate contraception for all fertile patients
  12. Negative pregnancy test

Exclusion criteria COHORT A

Subjects meeting any of the following criteria must not be enrolled in the study:

  1. Radiotherapy ≤ 4 weeks prior to enrolment.
  2. Other chemotherapy or biological therapy treatment ≤ 4 weeks prior to enrolment.
  3. Symptomatic brain metastases.
  4. Active infection.
  5. Gastro-intestinal abnormalities, inability to take oral medication, any condition affecting absorption.
  6. Impaired cardiac function including any of the following: uncontrolled hypertension (systolic >150 mmHg and/or diastolic > 100 mmHg) or clinically significant (i.e. active) cardiovascular disease: cerebrovascular accident/stroke or myocardial infarction within 6 months prior to first study medication; unstable angina; chronic heart failure (CHF) of New York Heart Association (NYHA) Grade II or higher (See Appendix 4); or serious cardiac arrhythmia requiring medication, baseline Left Ventricular Ejection Fraction (LVEF) ≤ 55% measured by echocardiography (ECHO).
  7. Major surgery in the two weeks prior to entering the clinical trial.
  8. Concurrent treatment with any other anti-cancer therapy.
  9. History of another neoplastic disease (except basal cell carcinoma of the skin or uterine cervix carcinoma in situ adequately treated), unless in remission for ≥ 5 years.
  10. Patient unable to comply with the study protocol owing to psychological, social or geographical reasons.
  11. Pregnant and lactating women.
  12. Patients with history of hypersensitivity to either IP or excipients.
  13. Men and women of childbearing potential who are not using an effective method of contraception.
  14. Participation in another clinical trial or treatment with any investigational product within 4 weeks prior to inclusion in this study.
  15. Subjects who have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment).
  16. Patient with unresolved hypokalaemia, hypomagnesemia or hypocalcaemia

Inclusion criteria COHORT B

  1. Histological/confirmed adenocarcinoma of the colon or rectum with metastatic disease not amenable to salvage surgery.
  2. The original tumour specimen must be RAS (KRAS exons 2 3 4; NRAS exons 2 3 4) wild type and SISH/FISH positive or IHC 2+/3+ positive in more than 50% cells.
  3. Age ≥18.
  4. ECOG PS 0-1.
  5. Measurable disease as defined by RECIST 1.1 criteria.
  6. Progression (PD) while on, or within 6 months from therapy with approved standard drugs.
  7. Unless otherwise contraindicated, patients must have received and failed fluoropyrimidines, oxaliplatin, irinotecan -containing regimens as previous therapies for metastatic disease.
  8. Patients having failed only one line of chemotherapy for their metastatic diseases are eligible if they have received:
  9. FOLFOXIRI;
  10. FOLFIRI after progression to adjuvant FOLFOX, occurred on treatment or within 6 months after treatment completion.
  11. Treatments with bevacizumab, aflibercept or regorafenib and cetuximab or panitumumab are allowed.
  12. Adequate hematological function as defined by: ANC <= 1.5 x 109/L, platelet count >=100 x 109/L, haemoglobin >= 10 g/dL
  13. Adequate renal function, as defined by: creatinine <= 1.5 x UNL

  14. Adequate hepato-biliary function, as defined by the following baseline liver function tests:

    1. total serum bilirubin <=1.5 upper normal limit (UNL)
    2. alanine aminotransferase (ALT), aspartate aminotransferase (AST) < 2.5xUNL
    3. alkaline phosphatase (AP) <= 2.5xUNL; if total alkaline phosphatase (AP) > 2.5xUNL, alkaline phosphatase liver fraction must be <= 2.5xUNL
  15. Adequate contraception for all fertile patients
  16. Negative pregnancy test

Exclusion criteria COHORT B

  1. Radiotherapy <= 4 weeks prior to enrolment.
  2. Other chemotherapy or biological therapy treatment ≤ 4 weeks prior to enrolment.
  3. Symptomatic brain metastases.
  4. Active infection.
  5. Gastro-intestinal abnormalities, inability to take oral medication, any condition affecting absorption.
  6. Impaired cardiac function including any of the following: uncontrolled hypertension (systolic >150 mmHg and/or diastolic > 100 mmHg) or clinically significant (ie active) cardiovascular disease: cerebrovascular accident/stroke or myocardial infarction within 6 months prior to first study medication; unstable angina; chronic heart failure (CHF) of New York Heart Association (NYHA) Grade II or higher (See Appendix 4); or serious cardiac arrhythmia requiring medication, baseline Left Ventricular Ejection Fraction (LVEF) ≤ 55% measured by echocardiography (ECHO).
  7. Major surgery in the two weeks prior to entering the clinical trial.
  8. Concurrent treatment with any other anti-cancer therapy.
  9. History of another neoplastic disease (except basal cell carcinoma of the skin or uterine cervix carcinoma in situ adequately treated), unless in remission for ≥ 5 years
  10. Patient unable to comply with the study protocol owing to psychological, social or geographical reasons.
  11. Pregnant and lactating women.
  12. Patients with history of hypersensitivity to either IP or excipients.
  13. Men and women of childbearing potential who are not using an effective method of contraception.
  14. Participation in another clinical trial or treatment with any investigational product within 4 weeks prior to inclusion in this study.
  15. Subjects who have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment).
  16. Patient with unresolved hypokalaemia, hypomagnesemia or hypocalcaemia.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cohort A
Trastuzumab and lapatinib
Drug: Trastuzumab, Lapatinib
Patients enrolled in Cohort A will receive lapatinib 1000 mg daily per os + trastuzumab 4 mg/kg iv load, followed by 2 mg/kg iv weekly. Patients will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever come first.
Experimental: Cohort B
Pertuzumab and Trastuzumab-emtansine
Drug: Pertuzumab, trastuzumab-emtansine

Patients enrolled in Cohort B will receive pertuzumab 840 mg iv load, followed by 420 mg iv Q3weeks + trastuzumab-emtansine 3.6 mg/kg iv on day 1 of each subsequent 3 week cycle.

Patients will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever come first.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Objective Response Rate according to RECIST 1.1 criteria
Time Frame: Time Frame: every 8 weeks (cohort A) or every 9 weeks (cohort B) from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months
Time Frame: every 8 weeks (cohort A) or every 9 weeks (cohort B) from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months

Secondary Outcome Measures

Outcome Measure
Time Frame
Description of the frequency and severity of Adverse Events based on the NCI -CTCAE V4.0
Time Frame: Time Frame: weekly (cohort A) or every 21 days (cohort B) from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months
Time Frame: weekly (cohort A) or every 21 days (cohort B) from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months
Progression Free Survival
Time Frame: Time Frame: every 8 weeks (cohort A) or every 9 weeks (cohort B) from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months
Time Frame: every 8 weeks (cohort A) or every 9 weeks (cohort B) from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Fondazione del Piemonte per l'Oncologia

Investigators

  • Study Chair: Salvatore Siena, MD, Grande Ospedale Metropolitano Niguarda - Milano

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2012

Primary Completion (Anticipated)

December 1, 2018

Study Completion (Anticipated)

June 1, 2019

Study Registration Dates

First Submitted

June 13, 2017

First Submitted That Met QC Criteria

July 18, 2017

First Posted (Actual)

July 21, 2017

Study Record Updates

Last Update Posted (Actual)

October 30, 2018

Last Update Submitted That Met QC Criteria

October 29, 2018

Last Verified

October 1, 2018

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 004-IRCC-10IIS-12
  • 2012-002128-33 (EudraCT Number)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Metastatic Colorectal Cancer

Clinical Trials on Trastuzumab, Lapatinib

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe